MCL1 and neoplasm: Inhibition of SK2/DES1 by opaganib has been shown to block Akt signaling [22,23,26,27,32], and downregulate the expression of the c-Myc [26,27,28,29,62] and Mcl-1 [28] proteins, resulting in inhibition of proliferation and promotion of tumor cell death.